CallX Accepted Into Deepgram Startup Program, Expands AI Powered Call Platform for Insurance Sales

CallX joins the Deepgram Startup Program to expand its AI powered call platform, helping insurance agents sell better ...

OS Therapies Initiates FDA BLA Filing for OST-HER2 to Prevent or Delay Recurrent Pulmonary Metastatic Osteosarcoma

Regenerative Medicine Advanced Therapy (RMAT) designation requests update submitted to FDA with recent biomarker data ...

OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program for Osteosarcoma Therapies

Innovation is urgent and direly needed as pediatric cancers remain the leading disease-based cause of pediatric death in the United States. OS Therapies is empowered to continue its groundbreaking ...

Revolution Medicines Conference: CEO Details Daraxonrasib Phase III Timeline, First-Line PDAC Push

CEO Mark Goldsmith outlined the company’s late-stage plans for its RAS(ON) inhibitor daraxonrasib, discussed expansion into first-line pancreatic cancer, and offered updates on colorectal cancer and e ...

Former Microsoft Quantum Program Manager Joins Haiqu to Lead Product Launch

Dr. Antonio Mei brings 10+ years experience in HPC, AI and quantum computing I look forward to leading the development ...